Compare ADMA Biologics Inc (ADMA) vs iShares JPMorgan USD Emerging Markets Bond ETF (EMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs iShares JPMorgan USD Emerging Markets Bond ETF — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.18B), while iShares JPMorgan USD Emerging Markets Bond ETF trades at $94.83. The key difference: iShares JPMorgan USD Emerging Markets Bond ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | EMB | |
|---|---|---|
Market Cap | $2.18B | — |
Sector | Health | Fixed Income |
52-Week High | $20.38 | $97.74 |
52-Week Low | $7.60 | $92.95 |
Enterprise Value | $2.25B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
EMB, the iShares J.P. Morgan USD Emerging Markets Bond ETF, trades at $95.24, up 0.31% over 24 hours. Technical indicators are mixed, with a neutral overall signal and bearish moving averages. Recent dividend distributions provide income, but key financial ratios are unavailable. News sentiment highlights yield-driven returns amid emerging market sovereign risks.
Outlook hinges on income from its 5.1% yield, with limited price upside expected. Risks include emerging market defaults and Federal Reserve policy shifts. Analysts rate it a hold, emphasizing diversification benefits but cautioning on macro triggers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →
